Cita APA

Lin, C., Hong, D. S., Martin, M., GARRALDA, E., Siu, L., & Schoffski, P. (2024). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Citación estilo Chicago

Lin, Chia-Chi, David S. Hong, Miguel Martin, Elena GARRALDA, Lillian Siu, y Patrick Schoffski. A Phase 2, Multicenter, Open-label Study of Anti-LAG-3 Ieramilimab in Combination With Anti-PD-1 Spartalizumab in Patients With Advanced Solid Malignancies. 2024.

Cita MLA

Lin, Chia-Chi, et al. A Phase 2, Multicenter, Open-label Study of Anti-LAG-3 Ieramilimab in Combination With Anti-PD-1 Spartalizumab in Patients With Advanced Solid Malignancies. 2024.